Table 4.

Summary of correlative study results and relation to clinical outcomes

Patient	Best response	Time to progression (months)	Change in tumor R2 β2 homodimer by in situ RT–PCR after 3-AP (Fig. 1)	Change in PBMC RRM2 after 3-AP (Fig. 2)	Change in PBMC dCTP pools after 3-AP (Fig. 3)
4	PD	1.3	Increased	Unchanged	Not done
6	SD	5.2	Increased	Not done	Not done
16	PD	2.7	Not done	Decreased	Not done
27	SD	8.3	Not done	Decreased	Not done
30	NE	NE	Not done	Not done	Significantly decreased
31	SD	13.8	Not done	Decreased	Significantly increased

All patients except patient 4 had normal liver function; patient 30 was not evaluable for response because of treatment discontinuation after 1 dose due to toxicity

PD progressive disease, SD stable disease, NE not evaluable, PBMC peripheral blood mononuclear cells